biostudies-literaturevan der Meer PFNIDDK NIH HHS7-16https://www.ebi.ac.uk/biostudies/studies/S-EPMC12926800biostudies-literatureUnknown121(1)The application of technologies to inactivate pathogens in pooled plasma products is nowadays the standard. The number of blood centres applying these technologies to platelet concentrates is steadily increasing. However, pathogen inactivation (PI) of red cell concentrates and whole blood (WB) is challenging, as the haemoglobin-containing red cells quench light, and therefore require a different approach. Three technologies are currently under active development: S-303 (Intercept), UV-C (Theraflex) and riboflavin/UV (Mirasol). The S-303 technology is used for PI of red cell concentrates and has seen significant technical and clinical development in the last decade. Using this technology, red cell both ATP and haemolysis levels conform to objective requirements. For the UV-C technology, onlVox sanguinisPathogen inactivation of red cell concentrates and whole blood: I. History, technologies and in vitro product preservation studies.PMC12926800R01 DK124115Klei TRLvan der Meer PFCancelas JAfalsePathogen inactivation of red cell concentrates and whole blood: I. History, technologies and in vitro product preservation studies.The application of technologies to inactivate pathogens in pooled plasma products is nowadays the standard. The number of blood centres applying these technologies to platelet concentrates is steadily increasing. However, pathogen inactivation (PI) of red cell concentrates and whole blood (WB) is challenging, as the haemoglobin-containing red cells quench light, and therefore require a different approach. Three technologies are currently under active development: S-303 (Intercept), UV-C (Theraflex) and riboflavin/UV (Mirasol). The S-303 technology is used for PI of red cell concentrates and has seen significant technical and clinical development in the last decade. Using this technology, red cell both ATP and haemolysis levels conform to objective requirements. For the UV-C technology, onl2026-01-01T00:00:00Z2026 Jan2026-07-16T18:32:36.616Z2026-07-11T03:07:57.973ZS-EPMC129268004115267410.1111/vox.70133